Trial Profile
Retrospective observational study to investigate the predictive factors about the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 13 Feb 2013 New trial record